ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Recent advancements in the treatment of boys and adolescents with hypogonadism
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 215760" data-attributes="member: 13851"><p><strong>Figure 4.<u> Effect of recombinant follicle-stimulating hormone (r-FSH) priming followed by r-FSH plus human chorionic gonadotrophin (hCG) treatment on serum anti-Müllerian hormone (AMH), as a Sertoli cell biomarker, and testosterone (T), as a Leydig cell biomarker, in patients with central hypogonadism</u>. Initial r-FSH treatment with 150IU/day for 30days increased Sertoli cell AMH secretion. The addition of hCG resulted in an increase of Leydig cell T secretion, which induced Sertoli cell maturation as reflected in the decline in AMH levels. The grey areas represent normal AMH levels for males with prepubertal T levels, corresponding to pubertal Tanner stage 1, on the left, and to Tanner 4–5 levels on the right. *p<0.05; **p<0.01; ***p<0.001. Modified with permission from Young et al.130 © 2005 The Endocrine Society.</strong></p><p><strong>[ATTACH=full]19233[/ATTACH]</strong></p></blockquote><p></p>
[QUOTE="madman, post: 215760, member: 13851"] [B]Figure 4.[U] Effect of recombinant follicle-stimulating hormone (r-FSH) priming followed by r-FSH plus human chorionic gonadotrophin (hCG) treatment on serum anti-Müllerian hormone (AMH), as a Sertoli cell biomarker, and testosterone (T), as a Leydig cell biomarker, in patients with central hypogonadism[/U]. Initial r-FSH treatment with 150IU/day for 30days increased Sertoli cell AMH secretion. The addition of hCG resulted in an increase of Leydig cell T secretion, which induced Sertoli cell maturation as reflected in the decline in AMH levels. The grey areas represent normal AMH levels for males with prepubertal T levels, corresponding to pubertal Tanner stage 1, on the left, and to Tanner 4–5 levels on the right. *p<0.05; **p<0.01; ***p<0.001. Modified with permission from Young et al.130 © 2005 The Endocrine Society. [ATTACH type="full"]19233[/ATTACH][/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
X (Twitter)
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Recent advancements in the treatment of boys and adolescents with hypogonadism
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top